Clarity Pharmaceuticals Ltd (CLRPF)
OTCMKTS · Delayed Price · Currency is USD
2.120
0.00 (0.00%)
Sep 5, 2025, 9:30 AM EDT
Clarity Pharmaceuticals Company Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.
The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.
It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer.
The company was incorporated in 2010 and is based in Sydney, Australia.
Clarity Pharmaceuticals Ltd
| Country | Australia |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Michelle Parker |
Contact Details
Address: National Innovation Centre Sydney, 2015 Australia | |
| Phone | 61 2 9209 4037 |
| Website | claritypharmaceuticals.com |
Stock Details
| Ticker Symbol | CLRPF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michelle Parker | Chief Executive Officer, MD and Executive Director |
| Dr. Alan John Taylor Ph.D. | Executive Chairman |
| David K. Green BEc., CA | Chief Financial Officer |
| Dr. Colin David Biggin Ph.D. | Chief Operating Officer and Non-Independent Executive Director |
| Dr. Matthew Harris BSc., M.B.A., Ph.D. | Chief Scientific Officer |
| Mary Bennett | Head of People and Culture |
| Shaemus Gleason | Executive Vice President of Operations |
| Dr. Othon Gervasio | Chief Medical Officer |
| Eva Lengyelova | Executive Vice President of Clinical Development |
| Robert Vickery | Company Secretary |